Last updated: October 13, 2026
Diflucan in Dextrose 5% Plastic Container is Pfizer’s intravenous fluconazole presentation, supplied as a ready-to-use solution in 5% dextrose. Its commercial profile is mature and largely commoditized. The active ingredient, fluconazole, has long been off patent, and generic intravenous products compete on price, availability, contract status, and hospital purchasing terms rather than on core molecular differentiation.
Pfizer does not report revenue for this specific presentation in its public filings. The product’s current financial trajectory therefore must be assessed through regulatory status, generic competition, hospital-use dynamics, and the historical decline of branded fluconazole after loss of exclusivity.
What is Diflucan in Dextrose 5% Plastic Container?
Diflucan in Dextrose 5% Plastic Container is an intravenous formulation of fluconazole, a triazole antifungal. The formulation combines fluconazole with 5% dextrose and is supplied in a flexible plastic container for infusion.
| Attribute |
Product profile |
| Brand |
Diflucan |
| Active ingredient |
Fluconazole |
| Dosage form |
Intravenous infusion |
| Diluent |
5% dextrose |
| Container |
Flexible plastic infusion container |
| Sponsor |
Pfizer, historically through its Roerig commercial organization |
| FDA application |
NDA 019949 is associated with Diflucan products |
| Primary use |
Treatment and prevention of susceptible fungal infections |
| Major hospital settings |
Inpatient, oncology, transplant, intensive care and immunocompromised-patient care |
The product is used for systemic Candida infections, cryptococcal disease, mucosal candidiasis and prophylaxis in selected high-risk patients. Fluconazole is generally administered intravenously when oral treatment is unsuitable or unreliable. FDA labeling describes dosing by indication, renal function and patient characteristics rather than by the dextrose container presentation itself (U.S. Food and Drug Administration, n.d.-a).
How does the Dextrose 5% formulation compete in the hospital market?
The principal commercial advantage is operational convenience. A ready-to-use premix can reduce pharmacy compounding, preparation time and certain manipulation risks. The advantage is limited because hospitals can substitute other fluconazole injection products or pharmacy-prepared solutions when procurement economics favor those options.
The formulation competes against:
- Generic fluconazole injection in dextrose.
- Generic fluconazole injection requiring pharmacy dilution.
- Fluconazole products in sodium chloride or other compatible infusion solutions.
- Oral fluconazole, where gastrointestinal absorption and clinical status permit.
- Alternative antifungals, including echinocandins and liposomal amphotericin B, for resistant, severe or empirically treated infections.
The product’s market position depends on four purchasing variables:
- Contract price and group purchasing organization terms.
- Availability during injectable-drug shortages.
- Container compatibility with hospital administration systems.
- Clinical preference for ready-to-administer products.
Dextrose 5% is widely available, but the container format does not create a durable barrier to substitution. Hospitals commonly maintain therapeutic interchange and generic substitution protocols for fluconazole.
When did Diflucan lose patent and market exclusivity?
Fluconazole’s core composition-of-matter protection expired years ago. The branded product no longer benefits from meaningful active-ingredient exclusivity in the United States.
| Event |
Approximate period |
Commercial effect |
| Original Diflucan development and U.S. launch |
Early 1990s |
Establishment of branded systemic antifungal franchise |
| Core fluconazole patent expiry |
Early 2000s |
Generic entry became possible |
| Generic oral and injectable competition |
Early to mid-2000s |
Rapid price and share erosion |
| Current market |
Mature post-exclusivity market |
Competition centered on supply, contracts and logistics |
The core U.S. patent commonly associated with fluconazole was U.S. Patent No. 4,404,216, which had an expiration date in the early 2000s after applicable patent-term rules. Any historical pediatric, formulation, manufacturing or regulatory exclusivity did not preserve meaningful present-day exclusivity for the Dextrose 5% plastic-container product.
What patents protect Diflucan in Dextrose 5% Plastic Container?
No material active patent estate is publicly associated with the current commercial value of this presentation. The principal patent barriers historically covered fluconazole itself and, in some cases, formulations or manufacturing processes. Those rights do not provide a current barrier against ordinary generic fluconazole injection.
| Patent category |
Relevance today |
| Fluconazole composition patent |
Expired |
| Basic intravenous formulation rights |
No meaningful current exclusivity identified |
| Dextrose-specific formulation claims |
Limited commercial significance if expired or nonblocking |
| Plastic-container technology |
Generally available and not specific to Pfizer |
| Method-of-use patents |
No broad current exclusivity expected for established labeled uses |
| Manufacturing know-how |
May affect cost and quality but is not a reliable market-exclusion right |
A generic manufacturer does not need to reproduce Pfizer’s branding or proprietary commercial packaging. It must meet FDA requirements for identity, strength, sterility, stability, container closure integrity and labeling. The ability to supply a ready-to-use fluconazole infusion can be commercially important, but it does not create a high-value patent moat.
What is the Orange Book status of Diflucan?
The Orange Book is relevant to the NDA and listed product information, but it does not restore exclusivity to fluconazole. The key commercial issue is whether the specific branded presentation remains actively marketed and whether generic applicants can rely on an abbreviated new drug application pathway.
Fluconazole is a small-molecule drug. Generic competitors generally pursue ANDA approval rather than the biosimilar pathway. Paragraph IV challenges were most relevant during the original generic-entry period, when applicants challenged listed patents before those patents expired. They are not a central current risk for an expired core molecule.
| Regulatory issue |
Assessment |
| FDA pathway for competitors |
ANDA |
| Biosimilar risk |
Not applicable |
| Paragraph IV risk today |
Low strategic relevance because core patents are expired |
| Orange Book value |
Regulatory reference and patent-listing record, not a current exclusivity barrier |
| Reference-product substitution |
High where approved generic presentations are therapeutically equivalent |
The FDA’s Drugs@FDA database and current Orange Book should be used for the latest marketing status, product listings and patent records because sterile injectable presentations can be withdrawn, relabeled or replaced without changing the broader status of fluconazole as an active generic market (U.S. Food and Drug Administration, n.d.-b; U.S. Food and Drug Administration, n.d.-c).
Which companies challenge or compete with Diflucan?
The competitive field includes generic injectable manufacturers and contract suppliers rather than branded challengers. Depending on the procurement period and national market, hospital fluconazole products may be supplied by companies such as Fresenius Kabi, Hikma, Sagent Pharmaceuticals, Baxter, Pfizer’s generic or legacy channels, and other approved manufacturers.
The competitive set changes frequently because sterile injectables are exposed to plant inspections, manufacturing interruptions, component shortages and discontinuations. A company may hold approval without being an active supplier in every channel.
How strong is the patent estate for generic fluconazole?
The patent estate is weak as a market barrier. The more relevant barriers are operational:
- Sterile manufacturing capacity.
- Validation of large-volume parenteral production.
- Reliable access to containers, ports and closures.
- FDA inspection outcomes.
- Stability data for the finished product.
- Hospital formulary and group-purchasing contracts.
- Working capital required to support low-margin inventory.
These barriers can produce temporary supply advantages, but they are not equivalent to patent exclusivity. A supplier with dependable availability can win contracts even when several products are technically substitutable.
What is the financial trajectory for Diflucan in Dextrose 5%?
The product’s financial trajectory is structurally downward from its branded peak. Pfizer does not disclose revenue, gross margin or unit volume for Diflucan in Dextrose 5% Plastic Container as a standalone SKU. Public company reporting typically aggregates products by broader therapeutic or geographic categories, preventing a precise product-level revenue calculation (Pfizer Inc., 2001-2023).
The trajectory has four phases:
Branded growth
Diflucan benefited from broad clinical use, oral bioavailability, physician familiarity and a relatively favorable safety profile. The branded franchise generated substantial revenue before generic entry.
Patent-expiry erosion
Once generic fluconazole became available, prices declined and institutional buyers shifted volume to lower-cost alternatives. The effect was strongest in oral dosage forms but also affected intravenous products.
Mature generic competition
The market moved from innovation-led pricing to procurement-led pricing. Pfizer’s branded presentation retained value where hospitals preferred established supply, ready-to-use packaging or a particular contract arrangement. That value was insufficient to preserve historical branded economics.
Low-growth hospital supply market
Current demand is tied to patient admissions, oncology and transplant volumes, fungal infection incidence, stewardship practices, and substitution by oral therapy or newer antifungals. Unit demand can remain stable while revenue declines because price competition intensifies.
| Financial driver |
Directional impact |
| Generic entry |
Strongly negative |
| Price competition |
Negative |
| Ready-to-use container |
Moderately positive |
| Hospital demand |
Stable to modest growth |
| Oral substitution |
Negative for IV volume |
| Injectable shortages |
Temporarily positive for available suppliers |
| New clinical indications |
Limited |
| Patent protection |
No current meaningful support |
What revenue exposure does Pfizer have from this product?
Pfizer’s current revenue exposure to this specific presentation is likely immaterial relative to its consolidated pharmaceutical portfolio, but the company does not publish a product-level figure that permits an exact calculation. Diflucan is a legacy product rather than a major growth driver in Pfizer’s current portfolio.
The commercial value is more likely to reside in residual institutional demand, supply contracts and portfolio continuity than in premium branded pricing. A product can remain commercially available even after its financial contribution becomes small because it supports customer relationships, manufacturing utilization or hospital formulary breadth.
What generic launch scenarios exist?
Scenario 1: Continued branded availability
Pfizer or a successor commercial channel maintains the product for hospitals that prefer the branded container or require supply continuity. Revenue remains low and price-sensitive.
Scenario 2: Generic substitution accelerates
Hospitals move most demand to approved generic fluconazole injection. Diflucan becomes a limited-use or contract-specific product, with further volume erosion.
Scenario 3: Supply disruption creates temporary value
A shortage at one or more generic plants increases demand for available branded inventory. This can improve short-term volume or pricing, but it does not change the long-term patent position.
Scenario 4: Intravenous demand contracts
Greater use of oral fluconazole, shorter hospital stays and antifungal stewardship reduce IV utilization. The premix product faces both generic price erosion and dosage-form substitution.
What litigation and settlement agreements affect Diflucan?
No current high-value patent litigation or settlement framework is central to the commercial outlook for Diflucan in Dextrose 5% Plastic Container. Historical Paragraph IV disputes involving fluconazole were tied to the timing of generic entry and expired patent rights.
Current legal exposure is more likely to involve:
- Product liability.
- Sterility and manufacturing claims.
- Labeling or pharmacovigilance matters.
- Hospital procurement disputes.
- Contract and supply obligations.
Those issues can affect individual suppliers but do not recreate molecular exclusivity for fluconazole.
How does Diflucan compare with newer antifungals?
| Product class |
Position versus Diflucan IV |
| Generic fluconazole IV |
Direct price competitor |
| Oral fluconazole |
Dosage-form substitute |
| Echinocandins |
Higher-cost alternative for severe or resistant Candida infections |
| Liposomal amphotericin B |
More toxic and costly, used in selected serious infections |
| Voriconazole and posaconazole |
Compete in selected molds and resistant fungal infections |
Diflucan remains clinically relevant because of its established use, broad familiarity and lower cost. It is vulnerable when resistance, severity of illness or suspected mold infection requires a newer agent.
Key Takeaways
- Diflucan in Dextrose 5% Plastic Container is a mature intravenous fluconazole product supplied in a ready-to-use hospital format.
- Fluconazole’s core patent protection expired in the early 2000s.
- The product has no meaningful current patent moat identified from its active ingredient, formulation or labeled uses.
- Generic competition determines price, volume and hospital purchasing outcomes.
- Pfizer does not disclose product-level revenue for this presentation.
- The financial trajectory is one of long-term branded erosion, with residual value tied to supply reliability and institutional contracts.
- Biosimilar risk is irrelevant because fluconazole is a small-molecule drug; ANDA-based generic competition is the applicable pathway.
- Temporary shortages can improve availability-based economics, but they do not alter the long-term commoditized market structure.
FAQs
Is Diflucan in Dextrose 5% still commercially available?
Availability can vary by NDC, package size, distributor and hospital contract. FDA product databases and current manufacturer listings determine whether a specific package remains actively marketed.
Can pharmacies substitute generic fluconazole for Diflucan IV?
Substitution depends on FDA therapeutic-equivalence status, state pharmacy law, hospital policy and the exact dosage form and concentration. Institutional substitution is common for equivalent injectable products.
Does the plastic container provide patent protection?
The plastic container itself generally does not provide meaningful market exclusivity. Its value is operational, involving convenience, compatibility and reduced pharmacy preparation.
Is fluconazole exposed to biosimilar competition?
No. Fluconazole is a chemically synthesized small molecule, so competitors use the ANDA generic-drug pathway rather than the biosimilar pathway.
What is the largest commercial risk for this product?
The largest risk is continued price and volume erosion from generic injectable products, oral substitution and hospital procurement pressure. Manufacturing interruptions can affect short-term supply but do not create durable exclusivity.
References
-
Pfizer Inc. (2001-2023). Annual reports and Form 10-K filings. Pfizer Investor Relations.
-
U.S. Food and Drug Administration. (n.d.-a). Diflucan (fluconazole) prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Patent and Trademark Office. (n.d.). Patent Center and patent term information for U.S. Patent No. 4,404,216. https://patentcenter.uspto.gov/
